Topical ozenoxacin 1% cream in impetigo: A systematic review and meta-analysis
DOI:
https://doi.org/10.66344/jpad.v33i2.2156Abstract
Impetigo is a prevalent bacterial skin infection of the youngsters. Ozenoxacin is a new quinolone topical antibacterial agent that was developed as a 1% cream for the treatment of impetigo. The purpose of this study, which included a systematic review and meta-analysis, was to map the research and present the effectiveness of ozenoxacin 1% topical cream for treating impetigo. From the beginning to the end of the study period [July 2022], a thorough search was conducted on the PubMed, Google Scholar, Cochrane library, and Science Direct databases. According to clinical judgment and bacteriological testing, relevant studies that reported the success rate of ozenoxacin 1% topical cream in treating impetigo were included. Meta-analysis was done using the open-source software "R". The odds ratio was calculated along with the 95% confidence interval. To assess the level of certainty of the generated result, the GRADEpro tool was used. This systematic review as well as meta-analysis included 4 clinical trials, two from Spain and two from the United States of America, with an approx. of 1,874 cases, 957 of which used ozenoxacin 1% topical cream and 917 of which used placebo treatment. The fixed effect model showed that the use of ozenoxacin 1% topical cream is more effective than the use of placebo based on clinical judgment [OR=2.16, 95% CI (1.77−2.65); P=<0.001; I2=1%] and based on bacteriological culture testing results [OR=4.15, 95% CI (3.08–5.57); P=<0.001; I2=27.5%]. There is no evidence of publication bias or heterogeneity. The generated evidence is classified as having a high level of certainty. With a high certainty level of evidence, this meta-analysis showed that ozenoxacin 1% topical cream effectively treats impetigo over a placebo for both children and adult patients.
References
1. Bowen AC, Mahé A, Hay RJ, et al. The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma. PLoS One. 2015;10(8):e0136789.
doi:10.1371/journal.pone.0136789
2. Cole C, Gazewood J. Diagnosis and treatment of impetigo. Am Fam Physician. 2007;75(6):859-64.
3. Karimkhani C, Dellavalle RP, Coffeng LE, et al. Global Skin Disease Morbidity and Mortality: An Update From the Global Burden of Disease Study 2013. JAMA Dermatol. 2017;153(5):406-12.
doi: 10.1001/jamadermatol.2016.5538.
4. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014;59(2):147-159.
doi:10.1093/cid/ciu296
5. Hirschmann JV. Impetigo: etiology and therapy. Curr Clin Top Infect Dis. 2002;22:42-51.
6. Hartman-Adams H, Banvard C, Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician. 2014;90(4):229-35.
7. Koning S, van der Sande R, Verhagen AP, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2012;1(1):CD003261. doi:10.1002/14651858.CD003261.pub3
8. Gropper S, Albareda N, Santos B, Febbraro S. Systemic bioavailability, safety and tolerability of topical ozenoxacin in healthy adult volunteers. Future Microbiol. 2014;9(8 Suppl):S11-S16.
doi:10.2217/fmb.14.82
9. García Ron G, Villa Arranz M. New therapeutic applications of ozenoxacin in superficial skin infections. Dermatol Rep. 2021;14(2):9289. Published 2021 Aug 5. doi:10.4081/dr.2021.9289
10. Torrelo A, Grimalt R, Masramon X, Albareda López N, Zsolt I. Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents. Dermatology. 2020;236(3):199-207.
doi:10.1159/000504536
11. Eudaley S. Ozenoxacin (Xepi) for the Treatment of Impetigo. Am Fam Physician. 2020;101(12):760-1.
12. Wren C, Bell E, Eiland LS. Ozenoxacin: A Novel Topical Quinolone for Impetigo. Ann Pharmacother. 2018;52(12):1233-7.
doi:10.1177/1060028018786510
13. Sahu JK, Mishra AK. Ozenoxacin: A Novel Drug Discovery for the Treatment of Impetigo. Curr Drug Discov Technol. 2019;16(3):259-64. doi:10.2174/1570163815666180502165014
14. Canton R, Morrissey I, Vila J, et al. Comparative in vitro antibacterial activity of ozenoxacin against Gram-positive clinical isolates. Future Microbiol. 2018;13:3-19. doi:10.2217/fmb-2017-0289
15. Yamakawa T, Mitsuyama J, Hayashi K. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002;49(3):455-65. doi:10.1093/jac/49.3.455
16. Santhosh P, Thomas MH. Ozenoxacin: A novel topical antibiotic. Indian J Dermatol Venereol Leprol. 2021;87(1):131-4.
doi:10.25259/IJDVL_191_20
17. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Published 2021 Mar 29. doi:10.1136/bmj.n71
18. Munn Z, Tufanaru C, Aromataris E. JBI's systematic reviews: data extraction and synthesis. Am J Nurs. 2014;114(7):49-54. doi:10.1097/01.NAJ.0000451683.66447.89
19. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17(1):1-12.
doi:10.1016/0197-2456(95)00134-4
20. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
Published 2019 Aug 28. doi:10.1136/bmj.l4898
21. Rosen T, Albareda N, Rosenberg N, et al. Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo: A Randomized Clinical Trial. JAMA Dermatol. 2018;154(7):806-13. doi:10.1001/jamadermatol.2018.1103
22. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153-60.
doi:10.1136/ebmental-2019-300117
23. Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol. 2013;66(7):726-35.
doi:10.1016/j.jclinepi.2013.02.003
24. Gropper S, Albareda N, Chelius K, et al. Ozenoxacin 1% topical cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial. Future Microbiol. 2014;9(9):1013-23.
doi:10.2217/fmb.14.78
25. Hebert AA, Albareda N, Rosen T, et al. Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients With Impetigo: Pooled Analysis of Phase 3 Clinical Trials. J Drugs Dermatol. 2018;17(10):1051-7.
26. Williamson DA, Monecke S, Heffernan H, et al. High usage of topical fusidic acid and rapid clonal expansion of fusidic acid-resistant Staphylococcus aureus: a cautionary tale. Clin Infect Dis. 2014;59(10):1451-4.
doi:10.1093/cid/ciu658
27. García Ron G, Villa Arranz M. New therapeutic applications of ozenoxacin in superficial skin infections. Dermatol Rep. 2021;14(2):9289. Published 2021 Aug 5. doi:10.4081/dr.2021.9289.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Mohammed Al-Dhubaibi, Saleh Bahaj, Ghada Mohammed, Ahmed Ibrahim AbdElneam, Hamdan Hamdan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
